In this view, strategies modulating Act-A signaling, mainly based on receptor ligand traps, have been successfully tested in animal models, where they have shown effectiveness in treating muscle atrophy, vascular disease, renal fibrosis, high-turnover bone disease, and anemia. This evidence concerns the gene ACTA1 and renal fibrosis.